ClinicalTrials.gg
RecruitingNCT07559175EPICUpdated Oct 1, 2026

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

A Phase 2 interventional study of NHS7108 and Zenpep® in Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) and Pancreatic Enzyme Abnormality, sponsored by Aimmune Nestlé Health Science US R&D, LLC. Recruiting at 39 sites in 7 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Aimmune Nestlé Health Science US R&D, LLC · Phase 2, Interventional, and Treatment

How we know

Updated Oct 1, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Exocrine Pancreatic Insufficiency with a site in United States — 11 open to participants now, 13 under way, 1 of them phase 3. Exocrine Pancreatic Insufficiency · United States.

Planned enrollment
10th of 59
66 · median 31
Started
2026
with 5 others
Phase 2
11 of 73
3 open now
Primary completion
2027-06
later than 5 of 12 live
Registered
71st of 73
by date

Among the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, this one is the 10th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 71st registered.

Exocrine Pancreatic Insufficiency

136 studies on the registry are indexed under Exocrine Pancreatic Insufficiency; 26 are open to participants now.

Browse Exocrine Pancreatic Insufficiency studies →

Open to participants now

11 of the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Exocrine Pancreatic Insufficiency studies recruiting now, 12 (63%) set no upper age limit and 5 (26%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase/pancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration.

Number of Participants:

The aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention.

Study Arms and Duration:

The total study duration for each participant will be about 100 days (approximately 14 weeks), including:

  • A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration.
  • A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2.
  • An end of treatment/early discontinuation visit within approximately 7 days of the last study intervention dose.
  • An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration.

Very low dose group: 10 mg NHS7108 (approximately 25,000 LU)/main meal and snack; 25,000 LU Zenpep/main meal and snack (50 mg NHS7108 [approximately 125,000 LU] per day; 125,000 LU Zenpep per day)

Low dose group: 20 mg NHS7108 (approximately 50,000 LU)/main meal and 10 mg NHS7108 (approximately 25,000 LU)/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack (80 mg NHS7108 [approximately 200,000 LU] per day; 200,000 LU Zenpep per day)

Medium dose group: 40 mg NHS7108 (approximately 100,000 LU)/main meal and 20 mg (approximately 50,000 LU) NHS7108/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack (160 mg [approximately 400,000 LU] NHS7108 per day; 400,000 LU Zenpep per day)

High dose group: 60 mg NHS7108 (approximately 150,000 LU)/main meal and 30 mg NHS7108 (approximately 75,000 LU)/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack (240 mg NHS7108 [approximately 600,000 LU] per day; 600,000 LU Zenpep per day).

The dose for participants \< 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU/kg/day.

03

Conditions studied

  • Exocrine Pancreatic Insufficiency (EPI)
  • Cystic Fibrosis (CF)
  • Pancreatic Enzyme Abnormality
  • Pancreatic Diseases

Keywords

  • EPIC
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant is a male or female between 18 to 85 years of age, inclusive, at the time of signing the .
  2. Participants with clinically confirmed* chronic established (not due to a transient clinical diagnosis, i.e., acute pancreatitis) EPI and with a clinical indication for PERT.
  3. CFA off PERT of \<80% at screening
  4. Normal (BMI) by age and sex to ensure participant's EPI is adequately controlled in the opinion of the investigator (BMI of at least 17.0 and no greater than 35.0 kg/m²)
  5. Standard-of-care medications are allowed (antibiotics, mucolytic agents, aerosols, antacids), if on stable doses for at least 1 month prior to baseline CFA and CNA assessments and must not be altered in dose or stopped during the study.
  6. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are allowed if on stable doses for at least 3 months prior to randomization. Participants should not start taking CFTR modulators during the duration of the study.
  7. use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    Male Participants:

    • Non-sterilized male participants are eligible to participate if they agree to one of the following starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up: Must agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), OR male participants with a female partner of must agree to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method). Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. These requirements also apply to participants in a same sex relationship.
    • Male participants must agree not to donate sperm starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.

    Female Participants:

    • Female participants of childbearing potential (as defined in Appendix 4) are eligible to participate if they meet the following criteria: Agree not to become pregnant during the clinical study period and until the end-of-study safety follow-up. Have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day 1. If heterosexually active, must agree to consistently use a form of highly effective birth control, in combination with a barrier method starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up, OR agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up. These requirements do not apply to participants in a same sex relationship.
    • Female participants of nonchildbearing potential are eligible to participate if one of the following conditions apply: Must have a confirmed clinical history of sterility (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, as confirmed by review of the participant's medical records, medical examination, or medical history interview). Must be as defined as: amenorrhea for at least 1 year prior to screening and a laboratory confirmed serum follicle-stimulating hormone (FSH) level ≥ 40 mIU/mL. Female participants on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use 1 of the non-estrogen hormonal highly effective contraception methods from screening until at and continuing throughout the clinical study period, and until the end-of-study safety follow-up if they wish to continue their HRT during the study.
    • Female participants must agree not to donate ova starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.
    • For WOCBP only, serum pregnancy test will be performed at screening and urine pregnancy tests will be performed at the timepoints outlined in the SoA.
    • The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  8. Participants are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  9. Participants agree not to participate in another interventional study while participating in the study.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Female participants who are breastfeeding at the time of screening.
  2. Previous GI surgery, except for non-invasive neonatal or early childhood procedures such as correction of hypertrophic pyloric stenosis, surgical correction of Meckel's diverticulum, volvulus, or intestinal intussusception. Hernia repair, appendectomy, cesarean section, tubal ligation, hysterectomy, polypectomy, hemorrhoidectomy, or cholecystectomy are allowed if performed at least 2 years before randomization and have no impact on intestinal transit or absorption.
  3. Participants on enteral feeding.
  4. Participants with celiac disease.
  5. Known allergy or adverse reaction history to any component of NHS7108, Zenpep®, omega-3 oil, and/or to any other product administered during the study, including the blue dye.
  6. Concurrent , at the discretion of the Investigator, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, and seasonal allergies and childhood asthma) or any other disorder that in the opinion of the Investigator may put the participant at greater safety risk, influence response to study intervention, or interfere with study assessments.
  7. Concurrent conditions having a clinically significant impact on GI motility function, with the exception of pancreatic insufficiency due to pancreatectomy or CP.
  8. Any significant clinical/laboratory/radiological sign of unstable or unexpectedly deteriorating respiratory disease during the study duration, at the discretion of the Investigator.
  9. Omega-3 supplements are prohibited during all the study periods and should be stopped at least 7 days prior to the baseline off-treatment fat absorption assessments.
  10. Participants starting new medications or changing dose within 1 month before baseline off-treatment screening assessments.
  11. Acute use of oral or intravenous antibiotics within 2 weeks prior to the first dose of study intervention.
  12. Treatment with any drug or device/treatment within the 30 days or 5 half-lives of the drug (whichever is longer) prior to first dose of study intervention.
  13. Participant has any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis at screening as judged by the Investigator OR as detailed below:

    • Estimated \< 60 mL/min at screening visit.
    • Total > 1.5 × (ULN) at screening visit.
    • Serum (ALT) or aspartate aminotransferase (AST) > 2 × ULN at screening visit.
  14. Positive (HIV) antibody test.
  15. Presence of surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
  16. Positive virus (HCV) antibody test result at screening or within 3 months prior to first dose of study intervention AND positive on reflex to hepatitis C RNA test.
  17. Concurrent drug or alcohol addiction that in the opinion of the Investigator would preclude participation and compliance with the study procedures.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Other
    Very Low Dose Group

    10 mg NHS7108 \[approximately 25,000 LU\]/main meal and snack; 25,000 LU Zenpep/main meal and snack.

    Drug: NHS7108 · Drug: Zenpep®

  • Other
    Low Dose Group

    20 mg NHS7108 \[approximately 50,000 LU\]/main meal and 10 mg NHS7108 \[approximately 25,000 LU\]/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack.

    Drug: NHS7108 · Drug: Zenpep®

  • Other
    Medium Dose Group

    40 mg NHS7108 \[approximately 100,000 LU\]/main meal and 20 mg NHS7108 \[approximately 50,000 LU\]/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack.

    Drug: NHS7108 · Drug: Zenpep®

  • Other
    High Dose Group

    60 mg NHS7108 \[approximately 150,000 LU\]/main meal and 30 mg NHS7108 \[approximately 75,000 LU\]/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack.

    Drug: NHS7108 · Drug: Zenpep®

Interventions

  • DrugNHS7108

    NHS7108 is the experimental drug. It is a recombinant, modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovorans and produced by fermentation of recombinant Escherichia coli. Unit dose strength: 10 mg (approximately 25,000 LU) per capsule.

  • DrugPancrelipaseStudies of PancrelipasePancrelipase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Zenpep® is the active comparator. It is a combination of lipases, proteases, and amylases. Unit dose strength: 25,000 LU per capsule.

06

What researchers measure

Primary outcomes

  1. Primary Objectives: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Number of participants reporting 1 or more adverse events. Events Meeting the AE Definition: * Any abnormal laboratory test results or other safety assessments including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator. * Exacerbation of a chronic or in or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. * New condition detected or diagnosed after study intervention administration even though it may have been present before the start of the study. * Signs, symptoms, or the clinical sequelae of a suspected intervention-intervention interaction. * Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication.

    Time frame: 14 days after NHS7108 Treatment

  2. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    A complete physical examination will be performed and include, at a minimum, assessments of general appearance, head, ears, eyes, nose, throat, neck (including thyroid), skin, cardiovascular system, respiratory system, GI system, musculoskeletal system, lymph nodes, and nervous system.

    Time frame: At screening and end-of-study/safety follow-up visit. A brief symptom-directed physical examination may be performed at all other visits and at any time throughout the study, as clinically indicated.

  3. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include vital sign measurement, which will include Blood Pressure. Units of measurement for Blood Pressure: Millimeters of mercury (mm Hg)

    Time frame: After 14 -day NHS7108 treatment

  4. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include vital sign measurement, which will include Heart Rate. Units of measurement for Heart Rate: Beats Per Minute (BPM)

    Time frame: After 14 -day NHS7108 treatment

  5. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include vital sign measurement, which will include respiratory rate measurement. Units of measurement for respiratory rate measurement: breaths per minute (bpm).

    Time frame: After 14 -day NHS7108 treatment

  6. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include vital sign measurement, which will include body temperature. Units of measurement for body temperature: degrees Celsius (°C).

    Time frame: After 14 -day NHS7108 treatment.

  7. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include 12-Lead electrocardiogram (ECG) recording. 12-lead ECG will be recorded as single bedside measurements using an ECG machine that automatically calculates the heart rate and measures: 1. PR interval (millisecond (ms)).

    Time frame: After 14 -day NHS7108 treatment

  8. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include 12-Lead electrocardiogram (ECG) recording. 12-lead ECG will be recorded as single bedside measurements using an ECG machine that automatically calculates the heart rate and measures: 2. QRS, and QT (QT interval corrected for heart rate using Fridericia's correction \[QTcF\]) intervals.

    Time frame: After 14 -day NHS7108 treatment

  9. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology tests: 1. Platelet count (x10E3/uL) 2. White Blood Cell count with differential (percent and absolute): Neutrophils (x10E3/uL)

    Time frame: 14-day after NHS7108 treatment

  10. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology: 3\. RBC count (x10E6/uL)

    Time frame: 14-day after NHS7108 treatment

  11. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology: 4\. Hemoglobin (g/dl) 5. Mean cell hemoglobin concentration (g/dl)

    Time frame: 14-day after NHS7108 treatment

  12. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology: 6\. RBC indices: Mean Corpuscular Volume (femtoliters (fL)).

    Time frame: 14-day after NHS7108 treatment

  13. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology: 7\. Mean Corpuscular Hemoglobin (picograms (pg)).

    Time frame: 14-day after NHS7108 treatment

  14. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Hematology: 8\. Hematocrit (%), 9. Reticulocytes (%), 10. WBC count with differential (percent and absolute): Lymphocytes (%), Monocytes (%), Eosinophils(%), Basophils (%).

    Time frame: 14-day after NHS7108 treatment

  15. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Coagulation: 1. Fibrinogen (mg/dL), Prothrombin time (Sec) , Activated partial thromboplastin time (Sec).

    Time frame: 14-day after NHS7108 treatment

  16. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Coagulation: 2. Prothrombin time (Sec) , 3. Activated partial thromboplastin time (Sec).

    Time frame: 14 -day after NHS7108 treatment

  17. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Clinical Chemistry: 1. Bicarbonate (mmol/L), 2. Sodium(mmol/L), 3. Potassium (mmol/L), 4. Chloride (mmol/L).

    Time frame: After 14 -day NHS7108 treatment

  18. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Clinical Chemistry: 5. Albumin (g/dL), 6. Total protein (g/dL).

    Time frame: After 14 -day NHS7108 treatment

  19. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Clinical Chemistry: 7. Blood glucose (fasting at screening only) (mg/dL), 8. Phosphate (mg/dL), 9. Calcium (mg/dL), 10. Urea (mg/dL), 11. Creatinine (mg/dL), 12. Uric acid/urate (mg/dL), 13. Total and direct bilirubin (mg/dL), 14. Triglycerides (mg/dL), 15. Total Cholesterol (mg/dL).

    Time frame: After 14 -day NHS7108 treatment

  20. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Clinical Chemistry: 16. Creatine kinase (U/L), 17. AST/SGOT (U/L), 18. ALT/SGPT (U/L), 19. Alkaline phosphatase 2 (U/L), 20. GGT (U/L), 21. Lactate dehydrogenase (U/L).

    Time frame: After 14 -day NHS7108 treatment

  21. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Routine Urinalysis: Leukocyte esterase, Protein, Urobilinogen, Ketones, Bilirubin, Microscopic examination (if blood, leukocytes, or protein is abnormal), Blood, pH, Nitrite, Specific gravity, Glucose. All the above urinalysis are reported in absolute units. They are semi-quantitative. Hence no units of measurement.

    Time frame: After 14 -day NHS7108 treatment

  22. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Pregnancy Testing. Highly sensitive serum Beta-HCG pregnancy test (mIU/mL) and urine pregnancy tests (no units)

    Time frame: Serum Beta-HCG pregnancy test (mIU/mL) (at screening) and urine pregnancy tests (at all other timepoints) as needed for women of childbearing potential.

  23. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Other Screening Tests: 1. Follicle Stimulating Hormone- FSH (IU/L).

    Time frame: Will be performed at screening in women with unconfirmed reproductive potential status only (to confirm postmenopausal state).

  24. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety

    Endpoint: Changes from baseline in safety parameters include clinical laboratory tests, which include- Other Screening Tests: 2. Serology: HIV antibody, hepatitis B surface antigen, and hepatitis C virus antibody, hepatitis B surface antibody and hepatitis B core antibody total. (No units)

    Time frame: 14 days after NHS7108 Treatment

  25. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety

    Endpoint: Change from baseline in the Coefficient of Nitrogen Absorption (CNA).CNA expresses the ratio between the amount of nitrogen absorbed and the amount of nitrogen provided with the diet. It will also be analyzed from the stool collection period. CNA is calculated as follows: nitrogen intake (g) - excreted nitrogen (g)/nitrogen intake (g), expressed as percentage (%).

    Time frame: After 14 days NHS7108 treatment

Other outcomes

  1. Exploratory Objective: A) The effect of different doses of NHS7108 administered for 14 days in participants with EPI on fat absorption

    Endpoint: 1. Change from baseline in the CFA. CFA expresses the ratio between the amount of fat absorbed and the amount of fat provided with the diet and is considered the gold standard for the evaluation of efficacy of PERT. It requires collection of stools produced over a 72-hour period within a timeframe of approximately 7 days at the end of each treatment period, while the participant consumes a controlled diet providing a predefined amount of fat.

    Time frame: After 14 day NHS7108 treatment

  2. Exploratory Objective: A) The effect of different doses of NHS7108 administered for 14 days in participants with EPI on fat absorption

    2\. Omega-3 absorption test: change from baseline in post-prandial EPA and DHA content of plasma over a 24-hour period after standard breakfast along with area under the plasma level of EPA- and DHA-time curve from 0 (before breakfast) to 24 hours post-prandial (AUC0-24) and maximum plasma level of EPA and DHA (Cmax).

    Time frame: 14 days after NHS7108 treatment

  3. Exploratory objective: B) Effects of NHS7108 on gastrointestinal (GI) symptoms

    Endpoint: 1.Change from baseline in the Gastrointestinal Symptom Rating Scale (included in the eDiary)

    Time frame: after 14-day NHS7108 treatment

  4. Exploratory objective: B) Effects of NHS7108 on gastrointestinal (GI) symptoms

    Endpoint: 2. Stool frequency as assessed by the eDiary

    Time frame: After 14-day NHS7108 treatment

  5. Exploratory objective: B) Effects of NHS7108 on gastrointestinal (GI) symptoms

    Endpoint: 3. Stool consistency as assessed by the Scale named: Bristol Stool Scale (included in the eDiary)

    Time frame: After 14-day NHS7108 treatment

07

Study locations

7 of 39 sites recruiting
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
    Not yet recruiting
  • University of Arkansas for Medical Sciences Hospital - University
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
    Not yet recruiting
  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr
    Los Angeles, California 90048, United States
    Not yet recruiting
  • Omnicure Clinical Research
    Doral, Florida 33172, United States
    Not yet recruiting
  • Advent Health Medical Group
    Orlando, Florida 32804, United States
    Not yet recruiting
  • Johnson County Clin-Trials (JCCT)
    Lenexa, Kansas 66219, United States
    Recruiting
  • Johns Hopkins Medicine - Pulmonary and Critical Care
    Baltimore, Maryland 21205, United States
    Not yet recruiting
  • Billings Clinic Hospital - Public
    Billings, Montana 59101, United States
    Not yet recruiting
  • University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital
    Cleveland, Ohio 44106, United States
    Not yet recruiting
  • The Ohio State University College of Medicine (OSUCOM)
    Columbus, Ohio 43210, United States
    Not yet recruiting
  • University of Oklahoma Health Sciences Center - Pediatrics Hospital - University
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
  • Penn State Health
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Vanderbilt University Medical Center - Pulmonary Hospital - University
    Nashville, Tennessee 37232, United States
    Not yet recruiting
  • Medical Center Medconsult Pleven, Lovech branch
    Lovech, 5500, Bulgaria
    Not yet recruiting
  • Medical Center Medconsult Pleven
    Pleven, 5800, Bulgaria
    Not yet recruiting
  • MC Hipokrat-N - Gastroenterology
    Plovdiv, 4000, Bulgaria
    Not yet recruiting
  • Medical Center Excelsior base 3
    Sofia, 1463, Bulgaria
    Not yet recruiting
  • MH Egészségügyi Központ - Gasztroenterológiai Osztály
    Budapest, 1062, Hungary
    Not yet recruiting
  • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly
    Budapest, 1082, Hungary
    Recruiting
  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika
    Csongrád, 6720, Hungary
    Recruiting
  • AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public
    Catania, Catania 95121, Italy
    Not yet recruiting
  • Humanitas Research Hospital
    Rozzano, Lombardy 20089, Italy
    Not yet recruiting
  • Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic
    Messina, Messina 98124, Italy
    Not yet recruiting
  • Azienda Ospedaliero Universitaria Careggi - Gastroenterologia
    Florence, 50134, Italy
    Not yet recruiting
  • IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica
    Milan, 20132, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Sant'Andrea
    Roma, 00189, Italy
    Not yet recruiting
  • WIP Warsaw IBD Point Profesor Kierkus
    Pomorskie, Warszawa 04-501, Poland
    Not yet recruiting
  • Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi
    Lodz, Łódź Voivodeship 93-357, Poland
    Not yet recruiting
  • Hospital Clinic De Barcelona - Cirug-ía General y Digestiva
    Madrid, Barcelona 46026, Spain
    Not yet recruiting
  • Hospital Universitario La Paz Hospital - University
    Madrid, Madrid 28046, Spain
    Not yet recruiting
  • Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA)
    Murcia, Murcia 30120, Spain
    Not yet recruiting
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
    Recruiting
  • H. General de Málaga - Endocrinología
    Málaga, 29010, Spain
    Recruiting
  • Hospital Universitario y Politecnico La Fe - Neumología
    Valencia, 46026, Spain
    Recruiting
  • Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital
    Liverpool, Merseyside L7 8XP, United Kingdom
    Not yet recruiting
  • Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice
    Belfast, Northern Ireland BT9 7AB, United Kingdom
    Not yet recruiting
    • Damian Downey · Contact
  • Greater Glasgow and Clyde
    Glasgow, G12 0XH, United Kingdom
    Not yet recruiting
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Oct 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 30, 2026
StartEst.
Oct 2026was Apr 2026
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
12 sites added, 3 sites removed. 27 sites changed recruiting status (21 now not yet recruiting, 6 now recruiting)
Show 27 sites
  • HonorHealth Research Institute · Scottsdale, United Statesno status→Not yet recruiting
  • Keck Hospital of USC · Los Angeles, United Statesno status→Not yet recruiting
  • Advent Health Medical Group · Orlando, United Statesno status→Not yet recruiting
  • Johnson County Clin-Trials (JCCT) · Lenexa, United Statesno status→Recruiting
  • Johns Hopkins Medicine - Pulmonary and Critical Care · Baltimore, United Statesno status→Not yet recruiting
  • University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital · Cleveland, United Statesno status→Not yet recruiting
  • The Ohio State University College of Medicine (OSUCOM) · Columbus, United Statesno status→Not yet recruiting
  • Medical Center Medconsult Pleven, Lovech branch · Lovech, Bulgariano status→Not yet recruiting
  • Medical Center Medconsult Pleven · Pleven, Bulgariano status→Not yet recruiting
  • MC Hipokrat-N - Gastroenterology · Plovdiv, Bulgariano status→Not yet recruiting
  • Medical Center Excelsior base 3 · Sofia, Bulgariano status→Not yet recruiting
  • MH Egészségügyi Központ - Gasztroenterológiai Osztály · Budapest, Hungaryno status→Not yet recruiting
  • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly · Budapest, Hungaryno status→Recruiting
  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika · Csongrád, Hungaryno status→Recruiting
  • Humanitas Research Hospital · Rozzano, Italyno status→Not yet recruiting
  • Azienda Ospedaliero Universitaria Careggi - Gastroenterologia · Florence, Italyno status→Not yet recruiting
  • IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica · Milan, Italyno status→Not yet recruiting
  • Azienda Ospedaliera Universitaria Sant'Andrea · Roma, Italyno status→Not yet recruiting
  • WIP Warsaw IBD Point Profesor Kierkus · Pomorskie, Polandno status→Not yet recruiting
  • Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi · Lodz, Polandno status→Not yet recruiting
  • Hospital Clinic De Barcelona - Cirug-ía General y Digestiva · Madrid, Spainno status→Not yet recruiting
  • Hospital Universitari Arnau de Vilanova de Lleida · Lleida, Spainno status→Recruiting
  • H. General de Málaga - Endocrinología · Málaga, Spainno status→Recruiting
  • Hospital Universitario y Politecnico La Fe - Neumología · Valencia, Spainno status→Recruiting
  • Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital · Liverpool, United Kingdomno status→Not yet recruiting
  • Greater Glasgow and Clyde · Glasgow, United Kingdomno status→Not yet recruiting
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdomno status→Not yet recruiting
Show 12 added (7 United States, 2 Italy, 2 Spain, 1 United Kingdom)
  • University of Arkansas for Medical Sciences Hospital - University · Little Rock, United States
  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr · Los Angeles, United States
  • Omnicure Clinical Research · Doral, United States
  • Billings Clinic Hospital - Public · Billings, United States
  • University of Oklahoma Health Sciences Center - Pediatrics Hospital - University · Oklahoma City, United States
  • Penn State Health · Hershey, United States
  • Vanderbilt University Medical Center - Pulmonary Hospital - University · Nashville, United States
  • AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public · Catania, Italy
  • Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic · Messina, Italy
  • Hospital Universitario La Paz Hospital - University · Madrid, Spain
  • Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA) · Murcia, Spain
  • Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice · Belfast, United Kingdom
Show 3 removed
  • University of Southern California University Hospital (USCUH) - Internal Medicine · Los Angeles, United States
  • Maine Medical Center - Division of Pulmonary and Critical Care Medicine · Portland, United States
  • H-T. Centrum Medyczne-Endoterapia · Śląskie, Poland
Oct 1, 2026
Start date
Apr 2026→Oct 2026
Oct 1, 2026
Contact
Study contact changed: h•••@parexel.com · •••1017→s•••@parexel.com · •••1416. See the current contact
Oct 1, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly · Budapest, HungaryContact s•••@gmail.com · •••0000→s•••@gmail.com · •••0000
  • H. General de Málaga - Endocrinología · Málaga, SpainContact added g•••@juntadeandalucia.es · •••0000
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    12 sites added, 3 sites removed. 27 sites changed recruiting status (21 now not yet recruiting, 6 now recruiting)
    Show 27 sites
    • HonorHealth Research Institute · Scottsdale, United Statesno status→Not yet recruiting
    • Keck Hospital of USC · Los Angeles, United Statesno status→Not yet recruiting
    • Advent Health Medical Group · Orlando, United Statesno status→Not yet recruiting
    • Johnson County Clin-Trials (JCCT) · Lenexa, United Statesno status→Recruiting
    • Johns Hopkins Medicine - Pulmonary and Critical Care · Baltimore, United Statesno status→Not yet recruiting
    • University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital · Cleveland, United Statesno status→Not yet recruiting
    • The Ohio State University College of Medicine (OSUCOM) · Columbus, United Statesno status→Not yet recruiting
    • Medical Center Medconsult Pleven, Lovech branch · Lovech, Bulgariano status→Not yet recruiting
    • Medical Center Medconsult Pleven · Pleven, Bulgariano status→Not yet recruiting
    • MC Hipokrat-N - Gastroenterology · Plovdiv, Bulgariano status→Not yet recruiting
    • Medical Center Excelsior base 3 · Sofia, Bulgariano status→Not yet recruiting
    • MH Egészségügyi Központ - Gasztroenterológiai Osztály · Budapest, Hungaryno status→Not yet recruiting
    • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly · Budapest, Hungaryno status→Recruiting
    • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika · Csongrád, Hungaryno status→Recruiting
    • Humanitas Research Hospital · Rozzano, Italyno status→Not yet recruiting
    • Azienda Ospedaliero Universitaria Careggi - Gastroenterologia · Florence, Italyno status→Not yet recruiting
    • IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica · Milan, Italyno status→Not yet recruiting
    • Azienda Ospedaliera Universitaria Sant'Andrea · Roma, Italyno status→Not yet recruiting
    • WIP Warsaw IBD Point Profesor Kierkus · Pomorskie, Polandno status→Not yet recruiting
    • Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi · Lodz, Polandno status→Not yet recruiting
    • Hospital Clinic De Barcelona - Cirug-ía General y Digestiva · Madrid, Spainno status→Not yet recruiting
    • Hospital Universitari Arnau de Vilanova de Lleida · Lleida, Spainno status→Recruiting
    • H. General de Málaga - Endocrinología · Málaga, Spainno status→Recruiting
    • Hospital Universitario y Politecnico La Fe - Neumología · Valencia, Spainno status→Recruiting
    • Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital · Liverpool, United Kingdomno status→Not yet recruiting
    • Greater Glasgow and Clyde · Glasgow, United Kingdomno status→Not yet recruiting
    • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdomno status→Not yet recruiting
    Show 12 added (7 United States, 2 Italy, 2 Spain, 1 United Kingdom)
    • University of Arkansas for Medical Sciences Hospital - University · Little Rock, United States
    • Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr · Los Angeles, United States
    • Omnicure Clinical Research · Doral, United States
    • Billings Clinic Hospital - Public · Billings, United States
    • University of Oklahoma Health Sciences Center - Pediatrics Hospital - University · Oklahoma City, United States
    • Penn State Health · Hershey, United States
    • Vanderbilt University Medical Center - Pulmonary Hospital - University · Nashville, United States
    • AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public · Catania, Italy
    • Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic · Messina, Italy
    • Hospital Universitario La Paz Hospital - University · Madrid, Spain
    • Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA) · Murcia, Spain
    • Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice · Belfast, United Kingdom
    Show 3 removed
    • University of Southern California University Hospital (USCUH) - Internal Medicine · Los Angeles, United States
    • Maine Medical Center - Division of Pulmonary and Critical Care Medicine · Portland, United States
    • H-T. Centrum Medyczne-Endoterapia · Śląskie, Poland
    Start date Apr 2026→Oct 2026
    Contact Study contact changed: h•••@parexel.com · •••1017→s•••@parexel.com · •••1416. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly · Budapest, HungaryContact s•••@gmail.com · •••0000→s•••@gmail.com · •••0000
    • H. General de Málaga - Endocrinología · Málaga, SpainContact added g•••@juntadeandalucia.es · •••0000
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07559175
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Sandrine Guillot
Contact
sandrine.guillot@parexel.com
+33 (0) 6 73 64 14 16
Monique Bunyan
study director · Aimmune Nestlé Health Science US R&D, LLC (Role: Associate Clinical Project Manager)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion